NX1
Nexalis Therapeutics Ltd
$0.0150
0.00%
Market cap
$4M
Turnover
—
Last price
$0.0150
Day change
0.00%
Announcements
14
Range, past year
Open 0.025 · Low 0.007 · Now 0.015 · High 0.026
Open NX1 in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NX1 momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
32/100
Wyckoff phase
Accumulation2d
Trend stage
Emerging
1 Day
+0.0%
1 Week
+66.7%
1 Month
+66.7%
RSI
71
Avg daily range
6.0%
Nexalis Therapeutics Ltd scores 32 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Accumulation, where it has been for 2 trading days. The weekly timeframe reads Distribution, which does not yet agree with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- Volume 2.5× 60-day avg
Points to watch
- 60d drawdown -30.8%
- High volatility (ATR 6.0%)
- Risk rating: Very High
- Composite downside risk elevated
NX1 announcements
Recent price-sensitive releases.
- 2026-09-01 Removal of draft wording in the directors report HY accounts Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
- 2026-08-31 Half Yearly Report and Accounts Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
- 2026-07-31 Jun26 Appendix 4C Cash Flow Report Commitments Test Entity - Second Quarter Cashflow Report
- 2026-07-31 Jun26 Quarterly Activities Report Commitments Test Entity - Second Quarter Activity Report
- 2026-07-06 Update on Funding Facility and Clinical Program
- 2026-05-28 Binding Letter of Intent to replace existing $53m facility
- 2026-05-28 Reinstatement to Official Quotation
More Health Care stocks
Most traded in the same sector.